This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
A forum of leading hepatologists, endocrinologists and clinical development experts stewarding advances in science, clinical research and therapeutics for nonalcoholic fatty liver disease and steatohepatitis
EVENTS
6th NASH Roundtable™ Forum – Clinical Trials with Non-Invasive Tests (NITs) Instead of Histology: Fact or Fancy?
More information »5th NASH Roundtable™ Virtual Forum – Is Digital Pathology a Game-Changer for Histology for NASH Drug Development?
More information »RESOURCES
Fact Sheet: NASH Roundtable™, leading clinical development experts addressing challenges in NASH drug development
View Fact Sheet »MEMBER CO-AUTHORED PUBLICATIONS
March, 2023
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Read More »
March, 2023
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Read More »
March, 2023
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Read More »
March, 2023
Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trials. Read More »